Drug Profile

Human amniotic epithelial cell therapy - Shanghai iCELL Biotechnology

Alternative Names: hAECs; hAESCs; Human amniotic epithelial stem cell therapy - Shanghai iCELL Biotechnology

Latest Information Update: 25 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai iCELL Biotechnology
Developer Peking University People's Hospital; Shanghai iCELL Biotechnology; The Second Affiliated Hospital of Chongqing Medical University
Class Cell therapies; Stem cell therapies; Urologics
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Phase I Graft-versus-host disease; Ovarian disorders; Parkinson's disease
Phase 0 Female genital diseases
Preclinical Autism spectrum disorder; Lymphomatous thyroiditis; Renal failure; Spinal cord injuries; Systemic lupus erythematosus; Uveitis
No development reported Bronchial fistula

25 Sep 2025 Phase I development in Graft-versus-host-disease (In adolescents, In children, In the elderly, Prevention, In adults) is ongoing in China (IV, Infusion) (Shanghai iCELL Biotechnology pipeline, September 2025)
25 Sep 2025 Phase-I clinical trials in Ovarian disorders (Parenteral) before September 2025 (Shanghai iCELL Biotechnology pipeline, September 2025)
25 Sep 2025 Preclinical trials in Autism-spectrum-disorder in China (Parenteral) before September 2025 (Shanghai iCELL Biotechnology pipeline, September 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com